Virginia L. Stauffer

Eli Lilly (United States) — United States

Medicine · Health Sciences

35h-index3.7kcitations131works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(65), Migraine and Headache Studies(31), Bipolar Disorder and Treatment(25), Treatment of Major Depression(15), Mental Health and Psychiatry(14)

Publications131 total

Evaluating the Content Validity of the Modified Neuropathy Total Symptom Score-6 Self-Administered (mNTSS-6-SA) in a Painful Diabetic Peripheral Neuropathy Population
Journal of Pain Research·2025Open Access
A Conceptual Model of Patient Experiences of Painful Diabetic Peripheral Neuropathy to Support Clinical Outcomes Assessment
Journal of Pain Research·2025· 1 citedOpen Access
Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment
Neurology and Therapy·2025Open Access
Point Prevalence of Causal Risk Factors and Treatment Utilization in Distal Sensory Polyneuropathy: A Retrospective Analysis of Commercial and Medicare Claims Data (P4-7.003)
Neurology·2025
Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
The Journal of Headache and Pain·2021· 1 citedOpen Access
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
Advances in Therapy·2021· 9 citedOpen Access
Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study
Patient·2021· 10 citedOpen Access
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials
The Journal of Headache and Pain·2021· 19 citedOpen Access
Discrete Choice Experiment to Understand Patient Preferences for Self-Injectable Preventive Treatments for Migraine – A quantitative pilot (4230)
Neurology·2021· 1 cited
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
Journal of Neurology·2021Open Access
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
The Journal of Headache and Pain·2021· 41 citedOpen Access
Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
Quality of Life Research·2020Open Access
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Cephalalgia·2020· 102 cited
Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
Quality of Life Research·2020· 8 citedOpen Access
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
The Journal of Headache and Pain·2020· 17 citedOpen Access
Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine
BMC Neurology·2020· 5 citedOpen Access
Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of Phase 3 studies in participants with migraine
Research Square (Research Square)·2020Open Access
High Frequency Episodic Migraine Shift to Low Frequency Episodic Migraine in Patients Treated with Galcanezumab (1772)
Neurology·2020
Patient Functioning and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study (4002)
Neurology·2020
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
BMC Neurology·2020· 1 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Bruce J. Kinon(28), Haya Ascher‐Svanum(15), Sara Kollack‐Walker(11), Lei Chen(10), Robert R. Conley(7), Shitij Kapur(7), John M. Kane(7), Hong Liu‐Seifert(5), Sheena K. Aurora(5), Vicki Poole Hoffmann(4), Jennifer Sniadecki(3), Jean-Pierre Lindenmayer(3), P.F. Buckley(3), Leslie Citrome(3), Shufang Wang(3), Jonathan Rabinowitz(3), Ivo Caers(3), Michael Case(3), Allen W. Nyhuis(3), Douglas E. Faries(3)